Abstract
Background
Undernutrition is one of the most common problems among people living with HIV, contributing to premature death and the development of comorbidities within this population. In Sub-Saharan Africa (SSA), the impacts of these often inter-related conditions appear in a series of fragmented and inconclusive studies. Thus, this review examines the pooled effects of undernutrition on mortality and morbidities among adults living with HIV in SSA.
Methods
A systematic literature search was conducted from PubMed, EMBASE, CINAHL, and Scopus databases. All observational studies reporting the effects of undernutrition on mortality and morbidity among adults living with HIV in SSA were included. Heterogeneity between the included studies was assessed using the Cochrane Q-test and I2 statistics. Publication bias was assessed using Egger’s and Begg’s tests at a 5% significance level. Finally, a random-effects meta-analysis model was employed to estimate the overall adjusted hazard ratio.
Results
Of 4309 identified studies, 53 articles met the inclusion criteria and were included in this review. Of these, 40 studies were available for the meta-analysis. A meta-analysis of 23 cohort studies indicated that undernutrition significantly (AHR: 2.1, 95% CI: 1.8, 2.4) increased the risk of mortality among adults living with HIV, while severely undernourished adults living with HIV were at higher risk of death (AHR: 2.3, 95% CI: 1.9, 2.8) as compared to mildly undernourished adults living with HIV. Furthermore, the pooled estimates of ten cohort studies revealed that undernutrition significantly increased the risk of developing tuberculosis (AHR: 2.1, 95% CI: 1.6, 2.7) among adults living with HIV.
Conclusion
This review found that undernutrition has significant effects on mortality and morbidity among adults living with HIV. As the degree of undernutrition became more severe, mortality rate also increased. Therefore, findings from this review may be used to update the nutritional guidelines used for the management of PLHIV by different stakeholders, especially in limited-resource settings.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12879-020-05706-z.
Keywords: Adults living with HIV, PLHIV, Sub-Saharan Africa, Undernutrition
Background
Human Immunodeficiency Virus (HIV) continues to be a significant global public health problem, with Sub-Saharan Africa (SSA) being the most significantly affected region [1, 2]. Globally, in 2018, an estimated 37.9 million people were living with HIV (PLHIV), and 1.1 million people died from Acquired Immunodeficiency Syndrome (AIDS) related illnesses worldwide [3], with 54% of PLHIV located in East and Southern Africa, 13% in Western and Central Africa, 16% in Asia and Pacific, and 6% in Western and Central Europe and North America [4]. Low and middle-income countries (LMICs), especially SSA, are the most affected region accounted for 68% of PLHIV in 2018 [2, 4]. Although there is no cure for HIV, antiretroviral therapy (ART) suppresses viral replication and increases the CD4 counts sufficiently to improve the survival rates and quality of life [5]. Despite these benefits, 23.3 million (62%) PLHIV were accessing ART in 2018 [4, 6] with low ART coverage in LMICs is mainly attributable to inaccessibility of health coverage [1].
Malnutrition refers to both undernutrition and overnutrition. Undernutrition is a state of inadequate intake of energy or nutrients to support the physiological function of the body. Due to the high prevalence of undernutrition, malnutrition often refers to undernutrition and the associated complications [7, 8]. Therefore, this review focused on undernutrition, which is the most common form of malnutrition in LMICs.
Despite the use of ART having been effective in reducing AIDS-related mortality and morbidities [9], not all patients living with HIV have the same response to therapy. Thus, additional factors, such as nutritional status, and potential negative effects on the immunologic response of PLHIV must be considered [10]. Undernutrition is the most common problem among PLHIV and a significant factor potentiating morbidities and mortality [10]. Although undernutrition and HIV are global challenges, once more, we see a higher prevalence of undernutrition in SSA [11]. Accordingly, in 2018, about 22.8% of undernourished people and 68% of PLHIV were living in SSA [2, 4, 12].
Undernutrition and HIV are found to be interwoven in a vicious cycle [13]. PLHIV are more vulnerable to developing undernutrition by different mechanisms. HIV is often accompanied by reduction in food intake due to: food insecurity, cognitive impairment or depression, medication-related nausea, and opportunistic infections (OIs) of mouth and oesophagus, which bring about painful swallowing [14]. In addition, HIV increases the energy requirements of HIV-infected adults by 10% for asymptomatic, and by 20–30% for symptomatic patients [15]. Conversely, undernutrition weakens the immune system and increases the risk of early mortality and morbidities [16, 17]. Previous studies have shown that undernutrition has a significant impact on mortality and morbidity in PLHIV [18–21], with even a minimal weight loss of up to 5% significantly increasing the risk of death [22]. Studies conducted elsewhere confirmed that low body mass index (BMI) at ART initiation hastened disease progression and increased the risk of OIs [9, 23].
To inform health program planners and policy-makers, current evidence-based findings are required. Although there is a general understanding that undernutrition and HIV are interrelated, a comprehensive systematic review and meta-analysis estimating the pooled effects of undernutrition on mortality and morbidity among adults living with HIV is lacking. Although there are primary studies reporting the effects of undernutrition on mortality and morbidity among adults living with HIV in SSA, they are highly fragmented and inconclusive. For example, some studies showed that undernutrition (BMI < 18.5 kg2) has a significant effect on mortality and morbidity [23–36], while others showed no significant impact on mortality and morbidity [19, 28, 37–40]. To the best of our knowledge, the above inconsistencies have not been well investigated. Therefore, this review aims to examine the effects of undernutrition on mortality and morbidities among adults living with HIV in SSA. Results obtained from this review will provide evidentiary inputs for program planners and decision-makers in designing strategies to reduce undernutrition related mortality and morbidities among PLHIV, particularly in LMICs.
Methods
Data sources and searching strategies
This systematic review and meta-analysis is designed to examine the effects of undernutrition on mortality and morbidity among adults living with HIV in SSA. The study protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO), University of York Centre for Reviews and Dissemination (ID: CRD42020161822). The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline was followed to report our results (Additional file 1) [41]. We searched articles published between 2002 and 2019, aligning with the first year in which the first WHO ART guidelines were distributed for developing countries [42]. A comprehensive search was conducted in the following databases: PubMed (contains MEDLINE), EMBASE (Elsevier), CINAHL (EBSCO), and Scopus (Additional file 2). Searches were limited to articles published in English and conducted on humans. Finally, the reference lists of included studies were screened for additional articles. Articles identified through the electronic search were exported and managed using Covidence, a primary screening and data extraction tool provided by Cochrane. The search from the above-mentioned databases was done using the following search terms:
Line1:“malnutrition” OR “undernutrition” OR “nutritional deficienc*” OR “malnourish*” OR “low Body Mass Index” OR “low BMI” OR “underweight” OR “nutritional status” “stunting” OR “Wasting” OR “underweight” OR “micronutrient deficienc*”.
AND
Line2: “HIV Infections” OR “HIV” OR “HIV-1” OR “HIV-2” OR “HIV infect*” OR “human immunodeficiency virus” OR “human immunedeficiency virus” OR “human immuno-deficiency virus” OR “human immune-deficiency virus” OR “((human immun*)OR (deficiency virus))” OR “acquired immunodeficiency syndrome” OR “acquired immunedeficiency syndrome” OR “acquired immunodeficiency syndrome” OR “acquired immune-deficiency syndrome” OR “((acquired immun*) OR (deficiency syndrome))” OR “HIV-positive” OR “Sexually Transmitted Diseases, Viral”.
AND
Line3: “Mortalit*” OR “incidence” OR “survival” OR “death rate” OR “risk factors” OR “time to death” OR “case fatality rate” OR “determinates” OR “mortality rate” OR “predictors” OR “opportunistic infect*” OR “AIDS related opportunistic infecti*” OR “morbidit*” OR “hospital admissions” OR “hospitalization” OR “herpes zoster” OR “bacterial pneumonia” OR “pulmonary TB” OR “extra-pulmonary TB” OR “tuberculosis” OR “TB” OR “oral candidiasis” OR “oesophageal candidiasis” OR “mouth ulcer” OR “diarrh*” OR “pneumocystis pneumonia” OR “central nervous system toxoplasmosis” OR “toxoplasmosis” OR “cryptococcal meningitis” OR “non-Hodgkins lymphoma” OR “Kaposi’s sarcoma” OR “cervical cancer” OR “herpes simplex” OR “cytomegalovirus” OR “AIDS defining disease”.
AND
Line 4: “Angola” OR “Benin” OR “Botswana” OR “Burkina Faso” OR “Burundi” OR “Cameroon” OR “Cape Verde” OR “Central African Republic” OR “Chad” OR “Comoros” OR “Republic of the Congo” OR “Democratic Republic of the Congo” OR “Cote d’Ivoire” OR “Djibouti” OR “Equatorial Guinea” OR “Eritrea” OR Ethiopia” OR “Gabon” OR “The Gambia” OR “Ghana” OR “Guinea” OR “Guinea-Bissau” OR “Kenya” OR “Liberia” OR “Madagascar” OR “Malawi” OR “Mali” OR “Mauritania” OR “Mauritius” OR “Mozambique” OR “Namibia” OR “Niger” OR “Nigeria” OR “Rwanda” OR “Sao Tome and Principe” OR “Senegal” OR “Seychelles” OR “Sierra Leone” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sudan” OR “Swaziland” OR “Tanzania” OR “Togo” OR “Uganda” OR “Zambia” OR “Zimbabwe”.
The PICO framework was used to determine the eligibility for the study:
✓ Participants/population: adults (defined as those aged ≥15 years) living with HIV.
✓ Intervention(s)/exposure(s) group: undernourished adults living with HIV.
✓ Comparator(s)/control group: well-nourished adults living with HIV.
✓ Outcomes of interests: mortality and morbidities among adults living with HIV.
Inclusion and exclusion criteria
The study selection was done by the primary author (AA) using a two-stage approach. Initially, studies were screened based on titles and abstracts. At this stage, all studies reporting mortality and morbidity among PLHIV were considered. Then, a full-text assessment based on the predetermined inclusion criteria was performed (Fig. 1). All observational studies (i.e., cross-sectional, case-control, and cohort) reporting effects of undernutrition on mortality and morbidly among adults living with HIV in SSA were considered for inclusion. However, only cohort studies reporting the adjusted hazard ratio were included in the meta-analysis as determination of cause and effect relationships requires a robust study design. Excluded were systematic reviews, animal studies, studies not reporting the outcome of interests, conference papers, and editorial comments. The reason for excluding conference papers was due to the inability to assess the quality of studies in the absence of their full texts. Furthermore, studies conducted among HIV-infected pregnant women were excluded as pregnancy by itself increased the risk of undernutrition, and nutritional assessment tools used for pregnant women are different from tools used for other adults [43]. Studies involving both HIV-infected and HIV-uninfected adults were excluded, unless data for HIV-infected adults were reported separately. Articles included only malnourished adults living with HIV were also not considered for this review as these lacked controls (i.e., well-nourished adults living with HIV).
Measurement of outcome variables
This systematic review focused on two outcomes. The first outcome was the effect of undernutrition on mortality among adults living with HIV. Undernutrition (underweight) was defined as a BMI of less than 18.5 kg/m2. The severity of undernutrition was classified as severe (BMI < 16 kg/m2), moderate (BMI 16–16.99 kg/m2), and mild (BMI 17–18.48 kg/m2) [44]. The second outcome was the effect of undernutrition on morbidities. Morbidity refers to the occurrence of any type of opportunistic infection, incidence of AIDS defined diseases, hospital admissions, and other types of illnesses related to HIV-infection as reported by each primary study. The pooled effects of undernutrition on mortality and morbidity were determined using the (adjusted) hazard ratios reported from primary studies. For the meta-analysis, only cohort studies reporting the adjusted hazard ratios were included, as described previously.
Quality appraisal
The quality of included studies was appraised using the Newcastle-Ottawa scale (NOS) risk-of-bias assessment tool for cross-sectional, cohort, and case-control studies [45]. The NOS is validated for case-control and cohort studies with grading from zero to ten for cross-sectional, and zero to nine for case-control and cohort studies [46]. The three components of the tool are: selection, comparability, and outcome/exposure. The selection part of this tool was graded from zero to five stars for cross-sectional studies, and zero to four stars for cohort and case-control studies. The comparability was graded from zero to two stars for all study designs. Lastly, the outcome/exposure was primarily related to the statistical analysis and cofounding handling mechanisms, which was graded from zero to three stars for all study designs.
During the quality appraisal, three (AA, DD, and DS) authors were involved, ensuring each study was appraised by two authors, with any disagreements between authors resolved through discussion. Finally, the quality score of each study was calculated as the sum of scores, thus ranging from zero to ten for cross-sectional studies, and zero to nine for cohort and case-control studies. Accordingly, articles receiving three or four stars in the selection, one or two stars in comparability, and two or three stars in outcomes were categorized as “good quality”. Articles with two stars in the selection, one or two stars in comparability, and two or three stars in outcomes, were classified as “fair quality”, whereas, a “poor quality” score was considered if the articles got zero or one-star(s) in the selection, or zero stars in comparability, or zero or one-star(s) in outcomes [47].
Data extraction
A standardized data extraction format was adopted and prepared based on the Joanna Briggs Institute (JBI) data extraction format [48]. The data extracted included the following: primary author, publication year, country/countries where the study was conducted, study design, study/follow-up period, sample size, sex/ gender of participants, mortality rate/morbidity rate, and adjusted hazard ratio/ adjusted odds ratio with 95% confidence intervals (CI). If further information or clarification was needed, the primary author of the original article was contacted through email. The article was excluded if, after at least two email attempts, the author did not respond. Before combining in a meta-analysis, the hazard ratios were transformed into a logarithmic scale as the hazard ratio was measured on a ratio (exponential) scale.
Data synthesis
A narrative synthesis approach was employed to present results, which were not included in the meta-analysis. A meta-analysis was performed using Stata™ Version 16 statistical software to estimate effect sizes. Effect sizes were expressed as log-adjusted hazard ratios (AHR) with their 95% CIs. In this meta-analysis, well-nourished adults living with HIV were considered as a reference (control) category. However, some primary studies reported AHR by considering undernourished adults living with HIV as a reference category, so to ensure consistency and uniformity, new AHRs with their 95% CIs were calculated by taking the reciprocal of the reported AHRs [49]. Primary studies reporting the AHR based on the severity of undernutrition were included in our subgroup analysis because they reported nutritional status in three (mild, moderate, and severe) categories rather than two categories (undernutrition versus well-nourished). Studies reporting nutritional status (BMI) as a continuous variable were addressed in the narrative review.
Heterogeneity, publication bias, and subgroup analyses
The presence of heterogeneity between included studies was assessed using Cochrane Q-test and I2 statistics. The I2 value can be interpreted as: 0 to 40% (might not be important); 30 to 60% (may represent moderate heterogeneity); 50 to 90% (may represent substantial heterogeneity); and 75 to 100% (considerable heterogeneity) [50]. In the case of significant heterogeneity, possible sources were investigated by performing univariate meta-regression analyses, and a random-effects meta-analysis model estimated the final effect size. Furthermore, to minimize random variations between primary studies, subgroup analyses were performed based on different variables (i.e., country where studies were conducted, degree of malnutrition, sample size, publication year, and quality score). We selected these variables because of the availability of data for these variables from most included studies. At last, the presence of publication bias was assessed using Egger’s and Begg’s tests at a 5% significance level [51].
Results
Identification of studies
A total of 4309 articles were identified from PubMed, EMBASE, Scopus, and CINAHL (Fig. 1). After the removal of 898 duplicates, 3411 studies remained and were screened for title and abstract. In the next step, 3320 articles were excluded based on titles and abstracts as these were not relevant for this review. The full text of 91 studies were downloaded and assessed based on the predefined inclusion criteria. An additional 43 full texts were excluded for the following reasons: 17 studies did not report data on the outcome(s) of interest [52–65], eight studies reported only descriptive results [66–76], six studies were conference presentations [77–82], six studies were not conducted in SSA [83–88], two studies focused on children (aged < 15 years) [89, 90], two studies focused on pregnant women [91, 92], one study included only malnourished adults [93], and one was a review paper [94]. Five articles were added from the reference lists of included articles, leading to 53 included studies. Of these, 33 studies were conducted on mortality, 18 studies on morbidity, and two on both morbidity and both morbidity. Finally, 40 studies were available for the meta-analysis. Of these, 23 studies were used to estimate the pooled effects of undernutrition on mortality. Seven studies were included in the subgroup analysis to determine the effects of the severity of undernutrition (mild, moderate, and severe) on mortality. The remaining ten studies were used to estimate the pooled effects of undernutrition on tuberculosis.
Description of included studies
In this systematic review, a total of 367,680 adults living with HIV were included across included articles with more than three quarters (76.2%) being females. Publication year of the included studies ranged from 2006 to 2019. The sample size of the included studies ranged from 71 in Kenya [95] to 68,378 in Tanzania [96]. Most were cohort studies (n = 47, 88.7%). From the 32 studies that reported the number of deaths or proportion of mortality, the highest (38%) mortality was reported from a study done in Kenya [95]; whereas the lowest (2%) proportion mortality was reported from a study done in Cote d’Ivoire [25]. From the 19 included studies to assess the effects of undernutrition on morbidities, 14 studies were done on TB, two studies on anaemia, and one study each for intestinal parasite (IP), AIDS-defining disease, and OIs. Of the18 studies that reported the number of morbidities or proportion of morbidity, the highest proportion of morbidity (65%) was recorded in a study conducted in Uganda [97]. Conversely, the lowest (2.4%) proportion of morbidity was reported from a study conducted in South Africa [32] (Table 1). In this review, 13 SSA countries and six multi-country based studies were represented. In this regard, more than half (55%) of the studies were conducted in Uganda (n = 8), Ethiopia (n = 13), and South Africa (n = 8) (Fig. 2).
Table 1.
Studies included assessing the effect of undernutrition on mortality | |||||||||
No |
Author (Publication Year) |
Study Design | Study/ follow-up period | Quality score | Sample size | Female N (%) | Mortality N (%) | Adjusted confounders for mortality | |
1. | Ferradini et al., (2006) [24] | Retrospective cohort | 2001–2004 | 5 | 1, 308 | 827 (63.2) | 243 (19) | Age, year of HAART initiation, type of ART regimen, follow-up site, sex, and baseline CD4 count | |
2. | Evans et al., (2012) [29] | Retrospective cohort | 2004–2009 | 8 | 8409 | 5204 (61.9) | 661 (7.9) | Hgb, CD4 count, aspartate transaminase, TB, age, and sex | |
3. | Palombi et al., (2009) [98] | Retrospective cohort | NR | 6 | 3, 749 | 2325 (62) | 393 (10.5) | Sex, age, baseline Hgb, baseline CD4 count, baseline HIV RNA level, WHO staging, ART adherence, and length of ART follow-up. | |
4. | Jerene et al., (2006) [99] | Cohort | 2003–2005 | 6 | 152 | 66 (43.4) | 24 (15.8) | TLC, WHO staging and Hgb | |
5. | Johannessen et al., (2008) [100] | Prospective cohort | 2003–2006 | 7 | 320 | 223 (69.7) | 95 (29.7) | Sex, WHO staging, ART start year, Hgb, TLC, and platelet count | |
6. | Moh et al., (2007) [25] | Cohort | 2002–2004 | 7 | 792 | 606 (76.5) | 18 (2) | WHO staging, Hgb, viral load, baseline CD4 count, follow-up CD4 count and follow-up viral load | |
7. | Brown et al., (2016) [39] | Cohort | 2008–2015 | 8 | 432 | 243 (56.3) | 74 (17.2) | Sex, age at enrolment, CD4 count at enrolment, year of enrolment, and route of HIV testing | |
8. | Tesfamariam et al., (2016) [18] | Retrospective cohort | 2006–2013 | 8 | 489 | 254 (51.9) | 87 (17.8) | Educational status, functional status, WHO staging, CD4 count, Hgb, previous OI, HIV related counselling | |
9. | Bastard et al., (2013) [31] | Cohort | 2004–2010 | 8 | 55,789 | 36,508 (65.4) | 1843 (3.3) | Sex, age, WHO staging, CD4 count, diagnosis of TB, eligibility to ART, and mode of entry to ART | |
10. | Dao et al., (2011) [101] | Prospective cohort | 2005–2007 | 7 | 661 | 661 (100) | 53 (8) | Country, age, WHO staging, diagnosis of TB, CD4 count, viral load, prophylaxis, Hgb, WBC, neutrophils count, platelet counts, potassium, chloride, sodium, hyponatremia, creatinine clearance, AST/ALT, and albumin | |
11. | Kouanda et al., (2012) [30] | Retrospective cohort | 2003–2008 | 8 | 5608 | 3926 (70) | 690 (12.3) | Age, sex, occupation, WHO staging, ART regimen, CD4 count, year of HAART initiation, and intensity of intervention | |
12. | Masiira et al., (2014) [102] | Prospective cohort | 1992–2011 | 8 | 374 | 204 (54.5) | 27 (7.21) | Age, sex, marital status, alcohol consumption, tobacco use, Hgb, CD4 count, WHO staging, viral load, malaria infection during follow-up, diarrhea, and viral load | |
13. | Teshome et al., (2015) [38] | Retrospective cohort | 2011–2012 | 6 | 1173 | 649 (55.3) | 47 (4) | Sex, gap b/n test and treatment, marital status, family size, facility type, CD4 count, age, INH prophylaxis, CPT prophylaxis, side effects, functional status, HIV status disclosure, educational status, TB, and WHO staging | |
14 | Chen et al., (2008) [103] | Retrospective cohort | 2004–2006 | 7 | 2, 838 | 1716 (60.5) | 376 (13.2) | Sex, age, and WHO staging | |
15. | Sieleunou et al., (2009) [104] | Retrospective cohort | 2001–2006 | 7 | 1, 187 | 660 (55.6) | 338 (28.5) | Sex, WHO staging, CD4 count, and Hgb | |
16. | Liu et al., (2011) [20] | Retrospective cohort | 2004–2009 | 7 | 8271 | 11,927 (65.3) | 1673 (9.2) | Hgb and MUAC | |
17. | Ssebutinde et al., (2018) [35] | Retrospective cohort | 2006–2012 | 7 | 8364 | 5308 (63.5) | 180 (2.1) | Age, sex, WHO staging, CD4 count, and level of education | |
18. | Maskew et al., (2013) | Retrospective cohort | 2004–2010 | 8 | 7354 | 4621 (62.8) | 333 (4.5) | Sex, age, CD4 count, and Hgb | |
19. | Geng et al., (2013) [105] | Retrospective cohort | 2007–2011 | 7 | 2633 | 1563 (59.4) | 42 (1.6) | Age, sex, CD4 count, baseline TB diagnosis, pregnancy at ART initiation, WHO staging, income, employment status, education, and distance from ART clinic | |
20. | Hoffmann et al., (2011) [106] | Retrospective cohort | 2003–2008 | 7 | 15,060 | 5455 (36.2) | 2658 (18) | Sex, age, WHO staging, TB symptoms, Hgb, viral load, and CPT | |
21. | Toure et al., (2008) [27] | Retrospective cohort | 2004–2007 | 6 | 10,211 | 7187 (70.4) | 1140 (11) | Sex, age, CD4 count, WHO staging, ART regimen, Type of HIV, and Hgb | |
22. | Damtew et al., (2015) [21] | Retrospective cohort | 2007–2011 | 6 | 784 | 485 (61.9) | 87 (11.1) | Marital status, educational status, functional status, WHO staging, CD4 count, anaemia, and TB co-infected | |
23. | Ayele et al., (2017) [23] | Retrospective cohort | 2012–2014 | 7 | 280 | 183 (65.4) | NR | Sex, age, educational level, residence, religion, occupation, marital status, alcohol, WHO staging, CD4 count, TB treatment, type of ART regimen, and prophylaxis | |
24. | Maman et al., (2012) [107] | Retrospective cohort | 2001–2010 | 7 | 24, 037 | 16,355 (68) | 568 (2.4) | HIV program, sex, age, WHO staging, initial CD4 count, updated CD4 count, and year of ART initiation | |
25. | Naidoo et al., (2018) [34] | Retrospective cohort | 2008–2010 | 6 | 948 | 547 (57.7) | 56 (5.9) | Age, sex, CD4 count, WHO staging, and TB | |
26. | Stringer et al., (2006) [108] | Cohort | 2004–2005 | 7 | 21,755 | 13,646 (62.7) | 1, 120 (5.1) | Age, ART non-adherence, sex, Hgb, CD4 count, WHO staging, and TB infection | |
27. | Hussen et al.,(2016) [19] | Retrospective cohort | 2006–2011 | 8 | 340 | 200 (58.8) | 42 (12.4) | Age, marital status, CD4 count, WHO staging, occupation, educational level, Fluconazole prophylaxis, and Baseline HAART | |
28. | Pac et al., (2015) [109] | Prospective cohort | 2010–2012 | 7 | 540 | 324 (60) | 39 (7.2) | Age, sex, CD4 count, Hgb, TB infections, and positive serum Cr Ag | |
29. | Tchounga et al., (2016) [110] | Cohort | 2014–2015 | 7 | 1825 | 1102 (60.4) | 221 (12.1) | Sex, age, year of ART initiation, WHO staging, CD4 count, and Hgb | |
30. | Nansera et al., (2012) [37] | Retrospective cohort | 2007–2010. | 6 | 386 | 142 (36.8) | 53 (13.7) | Sex, anaemia, CD4 cell count, and WHO staging | |
31. | Otwombe et al., (2014) [111] | Prospective cohort | 2003–2010 | 8 | 2221 | 1555 (70) | 242 (11) | Sex, time on ART, CD4 count, employment status, ever smoking, and ever TB | |
Prospective cohort | 2003–2010 | 4469 | 3480 (77.9) | 324 (7.2) | |||||
32. | Kendi et al., (2013) [95] | Retrospective cohort | 2005–2009 | 6 | 71 | 35 (49.3) | 27 (38) | Age, sex, CD4 count, on ART, and any anti-fungal therapy | |
33 | Zachariah et al., (2006) [112] | Cross-sectional | 2003–2005 | 9 | 1, 507 | 990 (65.7) | 190 (12.6) | Sex, age, WHO staging, CD4 count, and active TB | |
34 | Umanah et al., 2015) [18] | Cross-sectional | 2007–2010 | 8 | 947 | 490 (51.7) | NR | ART regimen, age, sex, site of TB, CPT prophylaxis, CD4 categories, Hgb, infiltrative cavitation change on X-ray, fibrotic change on X-ray, other OIs, comorbidity, and adverse events to medication | |
Studies included assessing the effect of undernutrition on morbidity | |||||||||
No | Author | Study Design | Study/ follow-up period | Sample size |
Female N (%) |
Morbidity N (%) | Adjusted for confounders for morbidities | ||
35. | Moore et al., (2007) [26] | Prospective cohort | 2003–2005 | 6 | 1042 | 765 (73.4) | 53 (5.1) | Sex, median age, CD4 count, viral load, prior TB treatment, participation in previous safe water/co-trimoxazole study | |
36. | Kufa et al., (2016) [32] | Prospective cohort | 2011–2012 | 7 | 634 | 513 (80.9) | 15 (2.4) | Sex, age, employed, ever smoked, alcohol drinking, duration since HIV test, on ART, current or prior ART use, current CPT use, previous TB treatment, and CD4 count | |
37. | Sabasaba et al., (2019) [96] | Retrospective cohort | 2011–2014 | 8 | 68,378 | 51,486 (75.3) | 3124 (4.6) | Age, sex, marital status, CD4 categories, WHO staging, CPT use, IPT status, ART status, and functional status at enrolment | |
38. | Worodria et al., (2011) [113] | Prospective cohort | NR | 7 | 219 | 157 (71.7) | 6 (3.8) | Age, Sex, TB ski test, C-reactive protein, Hgb, CD4 count, and WHO staging | |
39. | Ahmed et al., (2018) [33] | Retrospective cohort | 2010–2015 | 8 | 451 | 267 (59.2) | 119 (26.4) | Marital status, family size, substance use, previous TB, OIs, bed ridden, length of follow-up, WHO staging, Hgb, CD4 count, and IPT | |
40. | Tiruneh et al., (2019) [36] | Retrospective cohort | 2009–2012 | 8 | 600 | 356 (59.3) | 53 (8.8) | Age, CD4 count, sex, weight, WHO staging, functional status, CPT, previous TB treatment, and OI | |
41 | Nicholas et al., (2011) [114] | Prospective cohort | 2006–2008 | 7 | 28,323 | 18,968 (67.0) | 780 (9) pre 933 (5) pos | Residence, sex, age, history of ART use, TB history, and CD4 count | |
42. | Liu et al., (2015) [115] | Prospective cohort | 2004–2012 | 8 | 67,686 | 50,633 (74.8) | 7602 (11.2) | Age, sex, district, family size, years of enrolment, season of visit, MUAC, anaemia, CD4 count, WHO staging, ALT, CPT, IPT, non-adherence to ART, month on ART, ART regimen, and NNRTI | |
43. | Chang et al., (2015) [116] | Retrospective cohort | 2004–2012 | 8 | 32,611 | 22,106 (67.8) | 2021 (6.2) | Sex, ART at enrolment year, ART regimen, WHO staging, CD4 count, viral load, anaemia, and ART adherence | |
44. | Bjerrum et al., (2016) [117] | Prospective cohort | 2013–2014 | 7 | 473 | 304 (64.3) | 60 (12.7) | Age, sex, CD4 count, cough ≥2 weeks, and fever ≥2 weeks | |
45. | Temesgen et al., (2019) [40] | Retrospective cohort | 2012–2017 | 7 | 492 | 264 (53.7) | 83 (16.9) | Sex, CD4 count, WHO staging, functional status, Hgb, OIs, CPT, and IPT | |
46. | Mupfumi et al., (2018) [118] | Retrospective cohort | 2008–2011 | 7 | 254 | 172 (67.7) | 13 (5) | Sex, age, Hgb, CD4 count, viral load, and hepatitis B infection | |
47. | Hanrahan et al., (2010) [29] | Prospective cohort | 2003–2008 | 9 | 3, 456 | 2704 (78.2) | 226 (6.5) | On HAART, CD4 count, CPT use, income, employment status, and smoking ever | |
48. | Melkamu et al., (2013) [119] | Case-Control Study | 2011–2012 | 9 | 357 | 192 (53.8) | NR | Marital status, educational status, having diabetes mellitus, WHO clinical staging, and having separate kitchen | |
49. | Gedle et al., (2017) [120] | Cross-sectional | April–June 2016 | 10 | 323 | 204 (63.2) | 142 (35.9) | Residence, educational status, income, presence of animals, presence of toilet, source of water, WHO staging, and CD4 count | |
50. | Kyeyune et al., (2014) [97] | Cross-sectional | 2010–2012 | 9 | 400 | 277 (69.3) | 260 (65) | Sex, CD4 count, age, HART status, educational status, and employment status | |
51. | Ageru et al., (2019) [121] | Cross-sectional | October–December 2016 | 10 | 411 | 258 (62.8) | 150 (36.5) | Sex, marital status, educational level, HAART status, year live with virus, frequency of eating, CD4 count, and infection with intestinal parasite | |
52. | Chen et al., (2019) [122] | Prospective cohort | 2007–2009 | 8 | 572 | 334 (58.4) | 75 (13.1) | Loss of appetite, handgrip strength, sphygmomanometer test | |
53. | Hussen et al. (2017) [123] | Retrospective cohort | 2006–2011 | 8 | 340 | 200 (58.8) | 83 (24.4) | Educational level, baseline HAART, and INH prophylaxis |
ALT Alanine Transaminase, ART Antiretroviral Therapy, AST Aspartate Aminotransferase, CD4 Cluster of Differentiation 4, CPT Cotrimoxazole Preventive Therapy, HAART Highly Active Antiretroviral Therapy, Hgb Hemoglobin, HIV Human Immunodeficiency Virus, INH Isoniazid, IPT Isoniazid Preventive Therap, MUAC Mid Upper Arm Circumference, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor, NR Not reported, OI Opportunistic Infection, RNA Ribonucleic Acid, TB Tuberculosis, TLC Total Lymphocyte count, and WHO World Health Organization
Quality appraisal results
NOS quality scores ranged from five to nine for cohort studies and eight to ten for cross-sectional studies (Table 1). The mean quality score of the included studies was 7.34 (SD: 0.14). More than two-thirds (71.7%) of the included studies had good quality. Fair or poor quality scores of the cohort studies were mainly due to the following reasons: lack of descriptions of loss to follow-up (n = 14, 29.8%), shorter follow-up period (n = 30, 63.8%), lack of description of the derivation of the exposed group (n = 19, 40.4%), and lack description of the derivation of the non-exposed group (n = 16, 34%). All included studies controlled confounders through multivariable regression analysis. However, most of the cohort studies employed a single-arm study design (no control group). From 47 cohort studies included in our review, 14 (29.8%) of the studies lacked a description of the loss to follow-up. Furthermore, six cohort studies reported that their loss to follow-up rate was more than 20%. About 63.8% of the included cohort studies had a follow-up period of less than five years for mortality and/or less than two years for morbidities.
Narrative analysis
The effects of undernutrition on mortality
Five studies [95, 98, 102, 112, 124], which were not suitable for the meta-analysis, were included in the narrative analysis. A multi-county based retrospective cohort study involving 3749 adults living with HIV found that, as BMI increased in one unit, the hazard of death was reduced by 8% (AHR: 0.92, 95% CI: 0.87, 0.96) [98]. A Kenyan retrospective cohort study followed 71 adults living with HIV with a median follow up time of 201 days found that as BMI increased in one unit, the hazard of death decreased by 18% (AHR: 0.82, 95% CI: 0.68, 0.99) [95]. Another retrospective cohort study including 374 adults living with HIV from Uganda reported that adults living with HIV who had BMI < 17.5 kg/m2 were six-fold (AHR: 6.11, 95% CI: 2.3, 16.2) more likely to die as compared to well-nourished adults living with HIV. This study also documented that HIV positive adults, who had BMI between 17.5 and 18.49 kg/m2, were four times (AHR: 4.5, 95% CI: 1.54, 13.32) more likely to die than well-nourished adults living with [102]. Furthermore, a cross-sectional study involving 1507 participants conducted in Malawi reported that mild (AOR: AOR: 2.1, 95% CI: 1.2, 3.8), moderate (AOR: 2.4, 95% CI: 1.7, 6.3) and severe (AOR: 6, 95% CI: 4.6, 12.7) undernutrition were significantly associated with mortality [112]. Lastly, a cross-sectional study involving 947 adults living with HIV reported from South Africa found that severe undernourishment (AOR: 3.71, 95% CI: 1.89, 7.29) and BMI between 16 and 18.49 kg/m2 (AOR: 2.35, 95% CI: 1.3, 4.26) were significantly associated with mortality in PLHIV [124].
The effects of undernutrition on tuberculosis
From the 15 studies assessed respecting the effects of undernutrition on tuberculosis (TB), five studies were not suitable for meta-analysis [115–119]. A Tanzanian prospective cohort study followed 67,685 adults living with HIV with a median follow-up time of 24 months indicated that patients living with HIV with a BMI < 17 kg/m2 (AHR: 1.96, 95% CI: 1.83, 2.09), and BMI between 17 and 18.49 kg/m2 (AHR: 1.69, 95% CI: 1.58, 1.8) were at higher risk of TB [115]. An additional retrospective cohort study on 32,611 Nigerian adults living with HIV noted that within a median follow-up time of 29.2 months severely underweight [(BMI < 16 kg/m2 (AHR: 3.85, 95% CI: 2.75, 5.38)], and underweight [(BMI: 16–18.49 kg/m2 (AHR: 2.18, 95% CI: 1.80, 2.65)] adults living with HIV had a higher risk to be diagnosed with TB [116]. Furthermore, a retrospective cohort study conducted among 254 adults living with HIV in Botswana documented that, as BMI increased in one unit, the risk of TB reduced by 19% (AHR: 0.81, 95% CI 0.66, 1.00: P = 0.05) [118]. A case-control study undertaken with 357 adults living with HIV in Ethiopia reported that undernourished HIV positive adults had a higher risk of TB (AOR: 3.8, 95% CI: 2.39, 6.08) [119]. Another prospective cohort study done among 473 adults living with HIV in Ghana found that undernutrition significantly increased the risk of TB (AOR: 2.51, 95% CI: 1.15, 5.51) [117].
The effects of undernutrition on other morbidities
Five studies reported the effects of undernutrition on various morbidities in PLHIV [97, 120–123]. Two cross-sectional studies from Uganda involved 400 participants [97], and Ethiopia involved 411participants [121] showed that undernutrition significantly increased the risk of anaemia among PLHIV with prevalence ratio (PR): 2.43 (95% CI: 1.01, 5.26) and AOR: 2.96 (95% CI: 1.36, 6.39), respectively. A cross-sectional study conducted among 323 Ethiopian adults living with HIV reported that undernutrition was significantly associated with parasitic intestinal infections (AOR: 2.59, 95% CI: 1.36, 4.95) [120]. Furthermore, a Zambian prospective cohort study involving 572 participants found that moderate wasting was significantly associated with AIDS-defining illnesses (AOR: 2.40, 95% CI: 1.13, 5.10) [122]. At last, a retrospective cohort study conducted with 340 Ethiopian adults living with HIV showed that undernutrition was a significant risk of OIs (AHR: 2.27, 95% CI: 1.4, 3.6) [123].
Meta-analysis of the effects of undernutrition on mortality
A total of 30 cohort studies were included in the meta-analysis. Of these, 23 studies reporting nutritional status as well-nourished (BMI between 18.5 kg/m2 and 24.9 kg/m2) and undernourished (BMI < 18.5 kg/m2) were analyzed together. The remaining seven studies reporting undernutrition based on the three categories of mild, moderate, and severe were addressed in the subgroup analyses (Table 2). Of the 23 studies included in the meta-analysis, 17 studies showed that undernutrition has a significant effect on mortality in adults living with HIV [18, 21, 24, 25, 27–31, 34, 101, 105, 106, 110, 111]. However, six studies reported that undernutrition has no significant effect on mortality in this population [19, 35, 37–39, 99]. Finally, the pooled AHR of 23 cohort studies involving 125,790 individuals showed that undernourished adults living with HIV were two-fold (AHR: 2.1, 95% CI: 1.8, 2.4) more likely to die as compared to their well-nourished counterparts. The included studies exhibited substantial heterogeneity (I2 = 66.4% and Cochrane chi-squared test p-value < 0.001). As a result, a random-effects meta-analysis model was conducted to estimate the final pooled effect size (Fig. 3).
Table 2.
Variables | Subgroup | No of studies | Population (N) | AHR (95%CI) | (I2 (%) and Cochrane chi-squared test p-value) |
---|---|---|---|---|---|
Severity of undernutrition | Severe | 6 | 66, 110 | 2.3 (1.9, 2.8) | (45.5, 0.102) |
Moderate | 2 | 42, 308 | 1.8 (1.5, 2.5) | (52.3, 0.145) | |
Mild | 4 | 50, 754 | 1.4 (1.1, 1.8) | (60.9, 0.053) | |
Geographical locations | Eastern Africa | 9 | 14, 601 | 1.8 (1.1, 3.0) | (75.9, < 0.001) |
Western Africa | 3 | 16, 611 | 2.5 (1.9, 3.3) | (23, 0.273) | |
Sothern Africa | 8 | 36, 303 | 2.1 (1.8, 2.3) | (35.3, 0.147) | |
Multicounty | 3 | 58, 275 | 2.4 (1.3, 4.4) | (80, 0.007) | |
Sample size | ≥ 5, 470 | 6 | 103, 441 | 1.8 (1.5, 2.3) | (79.3, < 0.001) |
< 5, 470 | 17 | 22, 349 | 2.3 (1.9, 2.9) | (56.6, 0.002) | |
Publication year | ≤ 2012 | 9 | 45, 657 | 2.3 (1.9, 2.7) | (65.6, 0.003) |
> 2012 | 14 | 80, 133 | 1.9 (1.5, 2.4) | (68.2, < 0.001) | |
Quality score | Good | 13 | 93, 236 | 2.05 (1.7, 2.5) | (73.3, < 0.001) |
Fair/ poor | 10 | 32, 554 | 2.2 (1.7, 2.8) | (51.5, 0.029) |
The possible sources of heterogeneity were explored using a meta-regression model considering the following continuous variables as moderators: publication year, sample size, and quality. None of these factors were significantly associated with heterogeneity. Publication bias was assessed using a funnel plot. Since the funnel plot had a symmetric inverted shape, it is unlikely that there is publication bias (Fig. 4). To confirm this finding, objective statistical tests (Begg’s rank correlation and Egger’s linear regression tests) were conducted, which confirmed that there was no publication bias among studies used to estimate the effect of undernutrition on mortality with p = 0.5 and p = 0.8.
Subgroup analyses of effects of undernutrition on mortality
The subgroup analyses of this review showed that severely undernourished adults living with HIV were at higher risk of death (AHR: 2.3, 95% CI: 1.9, 2.8) as compared to mildly undernourished adults living with HIV (using six studies) [20, 100, 104, 107–109]. However, the mortality rate between moderately undernourished (two studies) and mildly undernourished (four studies) adults living with HIV was not statistically significant [(AHR: 1.8, 95% CI: 1.5, 2.5) [20, 107], and (AHR: 1.4, 95% CI: 1.1, 1.8)] [20, 30, 103, 107], respectively. Moreover, undernutrition on mortality is exacerbated in Western Africa as compared to other parts of SSA (AHR: 2.5, 95% CI: 1.9, 3.3) [25, 27, 30]. The subgroup analyses also indicated that undernutrition has a more significant effect on mortality in studies published before 2012 (AHR: 2.3, 95% CI: 1.9, 2.7) [24, 25, 27–30, 99, 101, 106] (Table 2).
Meta-analysis of effects of undernutrition on TB
A total of ten cohort studies involving 104,387 adults living with HIV were included in the meta-analysis. Of these ten studies, seven studies found that undernutrition has a significant effect on the occurrence of TB [26, 32, 33, 36, 96, 113, 114]. The remaining three studies found that undernutrition has no significant effect on the occurrence of TB [25, 28, 40]. The final overall pooled effect found that undernutrition has a significant effect on the occurrence of TB among adults living with HIV (AHR: 2.1, 95% CI: 1.6, 2.7) (Fig. 5). Significant heterogeneity (I2 = 75.2% and Cochrane chi-squared test p-value < 0.001) was observed; therefore, a random-effects meta-analysis model was computed to estimate the pooled effect. To investigate the possible sources of heterogeneity, a univariate random-effects meta-regression was done using continuous variables of publication year, sample size, quality as covariates [(Coefficient: − 0.03, p: 0.524), (Coefficient: − 2.71, p: 0.736) and (Coefficient: 0.31: 0.307) respectively]. Finally, publication bias between the included studies was also assessed using the funnel plot (Fig. 6) with confirmatory tests of publication bias done using Begg’s rank correlation and Egger’s linear regression tests. Accordingly, both test sets indicated there was no publication bias across included studies (p = 0.325 and p = 0.767).
Subgroup analyses of effects of undernutrition on TB
Subgroup analyses were performed based on geographical locations, sample size, and year of publication. Our subgroup analyses indicated that undernutrition has a higher effect (AHR: 2.2, 95% CI: 1.6: 2.9) on the occurrence of TB among adults living with HIV in studies done in Eastern Africa as compared to other parts of SSA. Interestingly, insignificant heterogeneity (I2 = 51%, p-value = 0.069) was observed between studies conducted in Eastern Africa. The subgroup analysis based on publication year and sample size found no significant difference in undernutrition’s effect on the occurrence of TB among adults living with HIV. However, a considerable heterogeneity difference was observed across these factors (Table 3).
Table 3.
Variables | Subgroup | No of studies | Population (N) | AHR (95%CI) | (I2 (%) and Cochrane chi-squared test p-value) |
---|---|---|---|---|---|
Geographical locations | Eastern Africa | 6 | 71, 182 | 2.2 (1.6, 2.9) | 51, 0.069 |
Other countries | 4 | 33, 205 | 1.8 (0.9, 3.5) | 84.9, < 0.001 | |
Sample size | ≥ 1, 000 | 4 | 101, 199 | 2.02 (1.4, 2.9) | 87.8, < 0.001 |
< 1, 000 | 6 | 3, 188 | 2.2 (1.3, 3.6) | 56.8, 0.041 | |
Publication year | ≤ 2012 | 5 | 33, 832 | 2.02 (1.2, 3.4) | 80.7, < 0.001 |
> 2012 | 5 | 70, 555 | 2.02 (1.5, 2.8) | 46.8, 0.111 |
Discussion
Despite encouraging recent scale-up of ART, nutrition-related early mortality from HIV is a persistent concern in SSA. Therefore, this systematic review and meta-analysis aimed to estimate the pooled effects of undernutrition on mortality and morbidity among adults living with HIV in SSA. To the best of our knowledge, this review is the first of its kind. The findings of this review highlighted that undernutrition significantly increases the risk of mortality and morbidity in adults living with HIV in SSA, and that, as the degree of undernutrition became more severe, mortality rate also increased.
The overall pooled estimate of 23 cohort studies involving 125,790 adults living with HIV indicated that undernourished adults living with HIV were two times (AHR: 2.1, 95% CI: 1.8, 2.4) more likely to die as compared to their well-nourished counterparts. Different mechanisms could explain the observed association between undernutrition and mortality. Undernutrition significantly impairs the immune response, which could increase the risk of developing and recurrence of OIs in the early phase of ART and ultimately contributing to early mortality. There is evidence that malnutrition adversely affects both innate and adaptive immunity systems, which are essential for defense against infections [125]. OIs are the leading cause of mortality among PLHIV, being responsible for more than 94% of AIDS-related deaths [126, 127].
Another mechanism explaining the effect of undernutrition on mortality could be due to its impact on the adherence level of ART. Different studies revealed that undernutrition is significantly associated with poor ART adherence levels [128, 129]. The effectiveness of HIV treatment depends on ART drug adherence. PLHIV are recommended to take their medications continuously and daily [130] as ART drug adherence is the proximal predictor of mortality [131, 132]. An additional possible explanation for the observed effect of undernutrition on mortality might be due to its impact on ART treatment failure [133]. PLHIV, who had a history of treatment failure or not taking their ART drug properly, are at higher risk of death as compared to those who had good treatment response or good adherence level to their ART drugs [134, 135].
This review found that, as the degree of undernutrition became more severe, mortality rate also increased. This dose-response relationship of undernutrition and mortality could result from the severity of malnourishment increasing the occurrence of OIs, which are the leading cause of mortality among PLHIV [16]. It is postulated that malnutrition and infection are interrelated in a vicious cycle [136]. Infections contribute to malnutrition through different means: increased metabolic demand, loss of appetite, and decreased absorption. On the contrary, malnutrition increases the risk of infections by causing immune deficiency, resulting in the persistence of malnutrition as the most common cause of immunodeficiency [16, 137].
The second outcome of this review demonstrated that undernutrition significantly increased the risk of developing morbidities among adults living with HIV. A meta-analysis of ten cohort studies involving 104,387 adults living with HIV showed that undernourished adults living with HIV were twice as likely to develop TB as compared to their well-nourished counterparts. Our finding is in line with a systematic review of cohort studies, which reported that a higher risk of TB was observed among adults with BMI < 18.5 kg/m2 [138]. This finding might be due to malnutrition’s weakening of the immune system and the concomitant increased risk of comorbidities including TB infections [139].
The relationship between malnutrition and TB has been well documented [140]. The bidirectional relationship is more accentuated among adults living with HIV, because HIV further weakened the immune system and increased the risk of TB. Evidence suggests that malnutrition increases the risk of disease progression from latent TB to active TB by weakening the immune system among adults living with HIV [141]. Besides, food insecurity may delay the health-seeking behavior, which results in late diagnosis and poor treatment adherence of TB [142]. This problem is more severe in SSA, where 68% of the PLHIV in 2018 lived [2, 4], and 23.2% of the world’s food-insecure people in 2015 lived [143]. On the other hand, TB can cause loss of appetite, malabsorption, and increase metabolic demand [144].
Finally, subgroup analyses confirmed that undernutrition appears to have a more deleterious effect on the occurrence of TB among adults living with HIV in Eastern Africa as compared to other parts of SSA. The possible explanation for this variance might be due to the economic differences across included countries. Likewise, the studies included in Eastern Africa were obtained from Ethiopia, Tanzania, and Uganda. According to the 2019 World Bank report, all three countries were classified as low-income [145]. Even though the clear association is not well known, poverty is widely recognized as the leading risk factor for TB [129]. Moreover, the accentuated effect of undernutrition on TB could be due to the clinical profile of the participants included in primary studies. As an example, more than half (54.6%) of the participants involved in an Ethiopian study were classified as WHO clinical stage III and IV [33]. Furthermore, about 44.5% of the participants involved in a Tanzanian study were classified as WHO clinical stage III and IV [96]. The more advanced HIV/AIDS disease stage coincides with the increased occurrence and the recurrence of OIs, including TB [146]. According to the recent Ethiopian National ARV treatment guidelines, adults living with HIV presenting with pulmonary TB are classified as WHO stage III and with extra pulmonary TB are classified as WHO stage IV [147].
What does this study add to what is known?
Although different clinical trials showed nutritional interventions have no effect on mortality [16, 148, 149], the lancet HIV commentary paper strongly recommended that nutritional supplementations for patients on ART should be continued because it could increase body weight, hasten physical and functional recovery, and improve work capacity and quality of life [150]. Similarly, the WHO recommends that severely undernourished adults living with HIV should be treated with therapeutic foods. Moderately undernourished adults living with HIV can be treated with supplementary foods. Besides, nutritional assessments for PLHIV should be done regularly [151]. Although undernutrition is the proximal risk factor increasing mortality and morbidity among adults living with HIV [152], a comprehensive review estimating the effects of undernutrition on mortality and morbidity in this vulnerable population in SSA is lacking. Our results showed that undernutrition increased the risk of death and TB among adults living with HIV by two-fold. For policy makers and program planners, highly credible evidence obtained from systematic reviews and meta-analyses are vital. Therefore, findings from this review may be used to update the nutritional guidelines used for the management of PLHIV by different stakeholders, especially in limited-resource settings.
Strengths and limitations
There are a number of strengths with this review. An extensive search strategy was undertaken. Explicit inclusion and exclusion criteria regarding population, exposure, control, and outcomes were used. Three authors were involved in the quality assessment. A homogenous exposure category (BMI < 18.5 kg/m2) was used rather than including studies that used different categories for the meta-analysis. Attempts were made to control the confounders by taking the AHR for the meta-analysis. Since the included studies exhibited considerable heterogeneity, advanced statistical analyses such as meta-regression were performed to identify possible heterogeneity sources. Most of the included studies used measured weight and height to calculate BMI from medical records rather than self-reported weight and height thereby avoiding recall biases.
Despite the above mentioned strengths, this review has some constraints that must be considered before interpreting results. This review included some studies with small sample sizes, potentially influencing findings. Our search limited to studies published in the English language, which may have resulted in the exclusion of a few essential studies. Many studies reported BMI in different categories making it difficult to include all studies in our meta-analysis. However, this variance has been addressed through subgroup analyses and qualitative analysis. Despite the use of AHR for our meta-analysis, most of the included primary studies used retrospective data. Thus, these studies did not include some important nutritional variables like socioeconomic status and dietary diversity. Furthermore, the actual effect of undernutrition on mortality could be confounded by undiagnosed acute diseases. This review included studies reported from 13 SSA countries and six multicounty based studies, which may yield underrepresentation of other SSA countries. Lastly, the majority of included studies used baseline BMI, but it changed continuously over time. Therefore, this result may not reflect the actual effects of malnutrition on mortality and morbidity.
Conclusion
This review found that undernutrition has significant effects on mortality and morbidity among adults living with HIV. As the degree of undernutrition became more severe, mortality rate also increased. Based on our findings, we recommended that nutritional assessment among adults living with HIV needs to be done regularly. Moreover, early screening of morbidities like TB among undernourished adults living with HIV is recommended. Furthermore, besides the management of malnutrition, comprehensive nutritional counselling to improve diet by consuming locally available needs to be reinforced at each visit for HIV care. Further studies are needed to examine the impact of nutritional interventions to improve nutritional status on mortality and morbidities among adults living with HIV. Finally, further follow-up studies considering malnutrition as exposure variable are needed to examine its actual effects on mortality and morbidities.
Supplementary Information
Acknowledgments
The authors want to extend their special thanks to the librarians working at the University of Technology Sydney Library for their kindness and generous support during literature searching. The authors also extend their heartfelt thanks to the authors of primary papers included in this review.
Abbreviations
- AHR
Adjusted hazard ratio
- AIDS
Acquired Immunodeficiency syndrome
- ART
Antiretroviral therapy
- BMI
Body mass index
- CI
Confidence interval
- HAART
Highly active antiretroviral treatment
- HIV
Human immunodeficiency virus
- LMICs
Low and middle-income countries
- NOS
Newcastle-Ottawa scale
- OIs
Opportunistic infections
- PLHIV
People living with human immunodeficiency virus
- SSA
Sub-Saharan Africa
- TB
Tuberculosis
- WHO
World health Organization
Authors’ contributions
AA: Conception of research protocol, study design, literature review, quality assessment, data extraction, data analysis, interpretation and drafting the manuscript. DD and DS: Conception of research protocol, study design, quality assessment, reviewing and editing the manuscript. PP: Interpretation of the data, reviewing, and editing the manuscript. All authors have read and approved the manuscript.
Funding
Funding was not available for this study.
Availability of data and materials
The data sets used and/or analyzed for this review are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors have declared that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Animut Alebel, Email: animut.a23@gmail.com.
Daniel Demant, Email: Daniel.Demant@uts.edu.au.
Pammla Petrucka, Email: pammla.petrucka@usask.ca.
David Sibbritt, Email: David.Sibbritt@uts.edu.au.
References
- 1.Kharsany AB, Karim QA. HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10:34–48. doi: 10.2174/1874613601610010034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.World Health Organization: HIV/Aids factsheets available at https://www.who.int/news-room/fact-sheets/detail/hiv-aids accessed date 03 Jan 2020.
- 3.UNAIDS: Global HIV & AIDS statistics—2019 fact sheet available at https://www.unaids.org/en/resources/fact-sheet accessed date 03 Jan 2020.
- 4.UNAIDS: FACT SHEET–WORLD AIDS DAY 2019 available at https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf accessed date 03 Jan 2020.
- 5.Centres for Disease Control and Prevention (CDC): HIV Treatment available at https://www.cdc.gov/hiv/basics/livingwithhiv/treatment.html accessed date 04 Jan 2020.
- 6.World Health Organization: Antiretroviral therapy (ART) coverage among all age groups available at https://www.who.int/gho/hiv/epidemic_response/ART/en/ accessed date 04 Jan 2020.
- 7.Maleta K. Undernutrition. Malawi Med J. 2006;18(4):189–205. [PMC free article] [PubMed] [Google Scholar]
- 8.World Health Organization: Nutritional care and support for people living with HIV/AIDS: a training course available at https://apps.who.int/iris/bitstream/handle/10665/44384/9789241591898_eng_Participant.pdf?sequence=3. accessed 15 Feb 2020; 2009.
- 9.Edmonds A, Yotebieng M, Lusiama J, Matumona Y, Kitetele F, Napravnik S, Cole SR, Van Rie A, Behets F. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med. 2011;8(6):e1001044. doi: 10.1371/journal.pmed.1001044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Clin Dev Immunol. 2012;2012. [DOI] [PMC free article] [PubMed]
- 11.Trehan I, O'Hare BA, Phiri A, Heikens GT. Challenges in the management of HIV-infected malnourished children in sub-Saharan Africa. AIDS Res Treat. 2012;2012:790786. doi: 10.1155/2012/790786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Food and Agriculture Organization of the United Nations: The state of food security and nutrition in the world available at http://www.fao.org/3/ca5162en/ca5162en.pdf accessed date 04 Jan 2019. In Rome; 2019.
- 13.Thimmapuram R, Lanka S, Esswein A, Dall L. Correlation of nutrition with immune status in human immunodeficiency virus outpatients. Mo Med. 2019;116(4):336–339. [PMC free article] [PubMed] [Google Scholar]
- 14.Weiser SD, Young SL, Cohen CR, Kushel MB, Tsai AC, Tien PC, Hatcher AM, Frongillo EA, Bangsberg DR. Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr. 2011;94(6):1729s–1739s. doi: 10.3945/ajcn.111.012070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kosmiski L. Energy expenditure in HIV infection. Am J Clin Nutr. 2011;94(6):1677s–1682s. doi: 10.3945/ajcn.111.012625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.França T, Ishikawa L, Zorzella-Pezavento S, Chiuso-Minicucci F, da Cunha M, Sartori A. Impact of malnutrition on immunity and infection. J Venomous Anim Toxins Incl Trop Dis. 2009;15(3):374–390. doi: 10.1590/S1678-91992009000300003. [DOI] [Google Scholar]
- 17.Enwonwu CO. Complex interactions between malnutrition, infection and immunity: relevance to HIV/AIDS infection. Nig J Clin Biomed Res. 2006;1(1):6–14. [Google Scholar]
- 18.Tesfamariam K, Baraki N, Kedir H. Pre-ART nutritional status and its association with mortality in adult patients enrolled on ART at fiche Hospital in North Shoa, Oromia region, Ethiopia: a retrospective cohort study. BMC Res Notes. 2016;9(1):512. doi: 10.1186/s13104-016-2313-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hussen S, Belachew T, Hussien N. Nutritional status and its effect on treatment outcome among HIV infected clients receiving HAART in Ethiopia: a cohort study. AIDS Res Ther. 2016;13:32. doi: 10.1186/s12981-016-0116-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Liu E, Spiegelman D, Semu H, Hawkins C, Chalamilla G, Aveika A, Nyamsangia S, Mehta S, Mtasiwa D, Fawzi W. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis. 2011;204(2):282–290. doi: 10.1093/infdis/jir246. [DOI] [PubMed] [Google Scholar]
- 21.Damtew B, Mengistie B, Alemayehu T. Survival and determinants of mortality in adult HIV/aids patients initiating antiretroviral therapy in Somali region, Eastern Ethiopia. Pan Afr Med J. 2015;22:138. doi: 10.11604/pamj.2015.22.138.4352. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hu W, Jiang H, Chen W, He S-H, Deng B, Wang W-Y, Wang Y, Lu CD, Klassen K, Zeng J. Malnutrition in hospitalized people living with HIV/AIDS: evidence from a cross-sectional study from Chengdu, China. Asia Pac J Clin Nutr. 2011;20(4):544. [PubMed] [Google Scholar]
- 23.Ayele T, Jarso H, Mamo G. Clinical outcomes of tenofovir versus zidovudine-based regimens among people living with hiv/aids: a two years retrospective cohort study. Open AIDS J. 2017;11:1–11. doi: 10.2174/1874613601711010001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet. 2006;367(9519):1335–1342. doi: 10.1016/S0140-6736(06)68580-2. [DOI] [PubMed] [Google Scholar]
- 25.Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483–2491. doi: 10.1097/QAD.0b013e3282f09876. [DOI] [PubMed] [Google Scholar]
- 26.Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21(6):713–719. doi: 10.1097/QAD.0b013e328013f632. [DOI] [PubMed] [Google Scholar]
- 27.Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22(7):873–882. doi: 10.1097/QAD.0b013e3282f768f8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, Chaisson RE, Gray GE, McIntyre JA, Martinson NA. Body mass index and risk of tuberculosis and death. AIDS. 2010;24(10):1501–1508. doi: 10.1097/QAD.0b013e32833a2a4a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Evans D, Maskew M, Sanne I. Increased risk of mortality and loss to follow-up among HIVpositive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(3):362–372. doi: 10.1016/j.oooo.2011.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. AIDS Care. 2012;24(4):478–490. doi: 10.1080/09540121.2011.630353. [DOI] [PubMed] [Google Scholar]
- 31.Bastard M, Nicolay N, Szumilin E, Balkan S, Poulet E, Pujades-Rodriguez M. Adults receiving HIV care before the start of antiretroviral therapy in sub-Saharan Africa: patient outcomes and associated risk factors. J Acquir Immune Defic Syndr. 2013;64(5):455–463. doi: 10.1097/QAI.0b013e3182a61e8d. [DOI] [PubMed] [Google Scholar]
- 32.Kufa T, Chihota V, Mngomezulu V, Charalambous S, Verver S, Churchyard G, Borgdorff M. The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: Implications for policy. BMC Infect Dis. 2016;16(1). [DOI] [PMC free article] [PubMed]
- 33.Ahmed A, Mekonnen D, Shiferaw AM, Belayneh F, Yenit MK. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: A retrospective cohort study. BMJ Open. 2018;8(2). [DOI] [PMC free article] [PubMed]
- 34.Naidoo K, Yende-Zuma N, Augustine S. A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection. Infect Dis Poverty. 2018;7(1). [DOI] [PMC free article] [PubMed]
- 35.Ssebutinde P, Kyamwanga IT, Turyakira E, Asiimwe S, Bajunirwe F. Effect of age at initiation of antiretroviral therapy on treatment outcomes; a retrospective cohort study at a large HIV clinic in southwestern Uganda. PLoS One. 2018;13(8):e0201898. doi: 10.1371/journal.pone.0201898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Tiruneh G, Getahun A, Adeba E. Assessing the impact of isoniazid preventive therapy (IPT) on tuberculosis incidence and predictors of tuberculosis among adult patients enrolled on ART in Nekemte town Western Ethiopia: a retrospective cohort study. Interdiscip Perspect Infect Dis. 2019;2019:1413427. doi: 10.1155/2019/1413427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, Graziano FM. Mortality and loss to follow-up among tuberculosis and HIV co-infected patients in rural southwestern Uganda. Int J Tuberc Lung Dis. 2012;16(10):1371–1376. doi: 10.5588/ijtld.11.0589. [DOI] [PubMed] [Google Scholar]
- 38.Teshome W, Moges M, Mekonnen E, Endrias M, Ayele S, Misganaw T, Shiferaw M, Tesema T. Do loss to follow-up and death rates from ART care vary across primary health care facilities and hospitals in South Ethiopia? A retrospective follow-up study. HIV/AIDS Res Palliat Care. 2015;7:167–174. doi: 10.2147/HIV.S85440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Brown JP, Ngwira B, Tafatatha T, Crampin AC, French N, Koole O. Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi. AIDS Res Ther. 2016;13(1). [DOI] [PMC free article] [PubMed]
- 40.Temesgen B, Kibret GD, Alamirew NM, Melkamu MW, Hibstie YT, Petrucka P, Alebel A. Incidence and predictors of tuberculosis among HIV-positive adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: a retrospective record review. BMC Public Health. 2019;19(1):1566. doi: 10.1186/s12889-019-7912-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. doi: 10.1016/j.jclinepi.2009.06.006. [DOI] [PubMed] [Google Scholar]
- 42.World Health Organization . Scaling up antiretroviral therapy in resource-limited settings. Geneva: World Health Organization; 2002. [Google Scholar]
- 43.Ververs MT, Antierens A, Sackl A, Staderini N, Captier V. Which anthropometric indicators identify a pregnant woman as acutely malnourished and predict adverse birth outcomes in the humanitarian context? PLoS Curr. 2013;5. [DOI] [PMC free article] [PubMed]
- 44.Purnell JQ: Definitions, Classification, and Epidemiology of Obesity. In: Endotext [Internet]. edn.: MDText. com, Inc.; 2018.
- 45.Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011. [Google Scholar]
- 46.Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Metaanal. 2017;5(4):80–84. [Google Scholar]
- 47.Penson D, Krishnaswami S, Jules A: Newcastle-Ottawa Quality Assessment Form for Cohort Studies. 2012. In.; 2018.
- 48.Peters M, Godfrey-smith P, Mcinerney P: Guidance for the conduct of JBI scoping reviews Joanna Briggs Institute Reviewer’s Manual South Australia: Joanna Briggs Institute 2019.
- 49.Kleinbaum D, Klein M, Pryor E. Logistic Regression A Self-Learning Text. Berlin: Springer; 2010. [Google Scholar]
- 50.Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;3(10). [DOI] [PMC free article] [PubMed]
- 51.Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785–794. doi: 10.1111/biom.12817. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, Eron JJ, Phiri S, van Oosterhout JJ. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510–518. doi: 10.1111/j.1468-1293.2010.00825.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Russell EC, Charalambous S, Pemba L, Churchyard GJ, Grant AD, Fielding K. Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010;10:433. doi: 10.1186/1471-2458-10-433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Koethe JR, Blevins M, Nyirenda CK, Kabagambe EK, Chiasera JM, Shepherd BE, Zulu I, Heimburger DC. Serum phosphate predicts early mortality among underweight adults starting ART in Zambia: a novel context for refeeding syndrome? J Nutr Metab. 2013;2013. [DOI] [PMC free article] [PubMed]
- 55.Molfino L, Kumar AM, Isaakidis P, Van den Bergh R, Khogali M, Hinderaker SG, Magaia A, Lobo S, Edwards CG, Walter J. High attrition among HIV-infected patients with advanced disease treated in an intermediary referral center in Maputo, Mozambique. Glob Health Action. 2014;7:23758. doi: 10.3402/gha.v7.23758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Bezabhe WM, Bereznicki LR, Chalmers L, Gee P, Kassie DM, Bimirew MA, Peterson GM. Adverse dug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia. Drug Saf. 2015;38(7):629–639. doi: 10.1007/s40264-015-0295-7. [DOI] [PubMed] [Google Scholar]
- 57.Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, et al. Gender differences in adherence and response to antiretroviral treatment in the Stratall trial in rural district hospitals in Cameroon. J Acquir Immune Defic Syndr. 2015;69(3):355–364. doi: 10.1097/QAI.0000000000000604. [DOI] [PubMed] [Google Scholar]
- 58.Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, Berhe M, Pugliese K, Binelli A, De Castro P, et al. Retention in care of adult HIV patients initiating antiretroviral therapy in Tigray, Ethiopia: A prospective observational cohort study. PLoS One. 2015;10(9). [DOI] [PMC free article] [PubMed]
- 59.Herce ME, Kalanga N, Wroe EB, Keck JW, Chingoli F, Tengatenga L, Gopal S, Phiri A, Mailosi B, Bazile J, et al. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. J Int AIDS Soc. 2015;18:19929. doi: 10.7448/IAS.18.1.19929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Stete K, Glass TR, van Dam GJ, Ntamatungiro A, Letang E, de Dood CJ, Corstjens PLAM, Ndege R, Mapesi H, Kern WV, et al. Effect of schistosomiasis on the outcome of patients infected with HIV-1 starting antiretroviral therapy in rural Tanzania. PLoS Negl Trop Dis. 2018;12(10). [DOI] [PMC free article] [PubMed]
- 61.Van Der Sande MAB, Van Der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A, Corrah T, Whittle HC. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr. 2004;37(2):1288–1294. doi: 10.1097/01.qai.0000122708.59121.03. [DOI] [PubMed] [Google Scholar]
- 62.Nakanjako D, Mayanja-Kizza H, Ouma J, Wanyenze R, Mwesigire D, Namale A, Ssempiira J, Senkusu J, Colebunders R, Kamya MR. Tuberculosis and human immunodeficiency virus co-infections and their predictors at a hospital-based HIV/AIDS clinic in Uganda. Intl J Tuberc Lung Dis. 2010;14(12):1621–1628. [PubMed] [Google Scholar]
- 63.Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56(4):349–355. doi: 10.1097/QAI.0b013e3181f9fb39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Hoffmann CJ, Chaisson RE, Martinson NA. Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One. 2014;9(1). [DOI] [PMC free article] [PubMed]
- 65.Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a south African cohort. Aids. 2005;19(18):2109–2116. doi: 10.1097/01.aids.0000194808.20035.c1. [DOI] [PubMed] [Google Scholar]
- 66.Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42(4):464–469. doi: 10.1097/01.qai.0000225729.79610.b7. [DOI] [PubMed] [Google Scholar]
- 67.Kasonka L, Makasa M, Marshall T, Chisenga M, Sinkala M, Chintu C, Kaseba C, Kasolo F, Gitau R, Tomkins A et al: Risk factors for subclinical mastitis among HIV-infected and uninfected women in Lusaka, Zambia. Paediatr Perinat Epidemiol 2006, 20(5):379–391. [DOI] [PubMed]
- 68.Donovan C, Massingue J. Illness, death, and macronutrients: adequacy of rural Mozambican household production of macronutrients in the face of HIV/AIDS. Food Nutr Bull. 2007;28(2 Suppl):S331–S338. doi: 10.1177/15648265070282S212. [DOI] [PubMed] [Google Scholar]
- 69.Estopinal CB, van Dijk JH, Sitali S, Stewart H, Davidson MA, Spurrier J, Vermund SH. Availability of volunteer-led home-based care system and baseline factors as predictors of clinical outcomes in HIV-infected patients in rural Zambia. PLoS One. 2012;7(12):e49564. doi: 10.1371/journal.pone.0049564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Henostroza G, Harris JB, Chitambi R, Siyambango M, Turnbull ER, Maggard KR, Krüüner A, Kapata N, Reid SE. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis. 2016;20(8):1033–1039. doi: 10.5588/ijtld.15.0651. [DOI] [PubMed] [Google Scholar]
- 71.Sørensen A, Jespersen S, Katzenstein TL, Medina C, da Silva TD, Correira FG, Hviid CJ, Laursen AL, Wejse C. Clinical presentation and opportunistic infections in HIV-1, HIV-2 and HIV-1/2 dual seropositive patients in Guinea-Bissau. Infect Dis. 2016;48(8):604–611. doi: 10.1080/23744235.2016.1180708. [DOI] [PubMed] [Google Scholar]
- 72.Bebell LM, Siedner MJ, Musinguzi N, Boum Y, Bwana BM, Muyindike W, Hunt PW, Martin JN, Bangsberg DR. Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. Int J STD AIDS. 2017;28(8):800–807. doi: 10.1177/0956462416671431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. North Am J Med Sci. 2013;5(6):367–370. doi: 10.4103/1947-2714.114169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo N, Moeng P, Maloba BR, Crewe-Brown HH, Brandt ME, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS. 2006;20(17):2199–2206. doi: 10.1097/QAD.0b013e3280106d6a. [DOI] [PubMed] [Google Scholar]
- 75.Oyella J, Meya D, Bajunirwe F, Kamya MR. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15(1). [DOI] [PMC free article] [PubMed]
- 76.Tadege M. Time to death predictors of HIV/AIDS infected patients on antiretroviral therapy in Ethiopia. BMC Res Notes. 2018;11(1). [DOI] [PMC free article] [PubMed]
- 77.Asiimwe SB, Laker-Oketta M, Bennett J, Mocello A, Glidden D, Haberer J, Bwana M, Hunt P, Bangsberg D, Mbidde E et al: Impact of Kaposi sarcoma on survival in HIV-infected African adults on antiretroviral therapy. In: Topics in Antiviral Medicine vol. 22; 2014: 51.
- 78.Herce ME, Kalanga N, Crocker JT, Wroe EB, Keck JW, Chingoli FD, Gopal S, Bazile J, Beste JA, Rigodon J: HIV-associated Kaposi sarcoma treated with chemotherapy and ART in rural Malawi. Topics in Antiviral Medicine 2015, 23((Chingoli F.D.) Ministry of Health of the Republic of Malawi, Neno, Malawi):319–320.
- 79.Kilama BK, Moshiro C, Todd J, Ramadhani A, Mmbando D: Patient level findings: Pre-ART mortality and its determinants in Tanzania public-driven HIV care program (2004–2011). Topics in Antiviral Medicine 2015, 23((Todd J.) London School of Hygiene and Tropical Medicine, London, United Kingdom):497–498.
- 80.Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS: Outcomes of multidrug resistant tuberculosis treatment among human immunodeficiency virus co-infected patients taking anti-retroviral treatment at Sizwe Tropical Disease Hospital Johannesburg, South Africa. International Journal of Infectious Diseases 2016, 45((Nyasulu P.S.) Monash University, Johannesburg, Gauteng, South Africa):403.
- 81.Adebamowo SN, Adebamowo CA, Odutola M, Famooto A, Adebayo A, Alabi B, Obende K, Offiong R, Ologun S, Achara P, et al. Incidence, persistence, and determinants of human papillomavirus: a prospective cohort study of HIV-negative Nigerian women. J Glob Oncol. 2017;3(2):39S–40S. doi: 10.1200/JGO.2017.009498. [DOI] [Google Scholar]
- 82.Hector J, Vinikoor MJ, Musukuma K, Chilengi R, Jefferys L, Hobbins MA, Davies MA, Egger M, Wandeler G. Mortality of HIV/HBV coinfected patients on art in urban and rural Southern Africa. Topics Antivir Med. 2017;25(1):241s. [Google Scholar]
- 83.Argemi X, Dara S, You S, Mattei JF, Courpotin C, Simon B, Hansmann Y, Christmann D, Lefebvre N. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. AIDS. 2012;26(9):1161–1166. doi: 10.1097/QAD.0b013e328353f363. [DOI] [PubMed] [Google Scholar]
- 84.Benova L, Fielding K, Greig J, Nyang'wa BT, Casas EC, da Fonseca MS, du Cros P. Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe. PLoS One. 2012;7(4). [DOI] [PMC free article] [PubMed]
- 85.Choun K, Thai S, Pe R, Lorent N, Lynen L, van Griensven J. Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg. 2013;107(4):235–242. doi: 10.1093/trstmh/trt001. [DOI] [PubMed] [Google Scholar]
- 86.Sharma A, Hoover DR, Shi Q, Gustafson D, Plankey MW, Hershow RC, Tien PC, Golub ET, Anastos K. Relationship between body mass index and mortality in HIV-infected HAART users in the women's interagency HIV study. PLoS One. 2015;10(12). [DOI] [PMC free article] [PubMed]
- 87.Kumar N, Aithal S, Unnikrishnan B, Ramapuram J, Thapar R, Mithra P, Kulkarni V, Holla R. Predictors of mortality among a cohort of HIV/AIDS patients on anti-retroviral therapy in coastal South India. HIV AIDS Rev. 2017;16(1):18–23. doi: 10.5114/hivar.2017.65124. [DOI] [Google Scholar]
- 88.Jiang J, Qin X, Liu H, Meng S, Abdullah AS, Huang J, Qin C, Liu Y, Huang Y, Qin F, et al. An optimal BMI range associated with a lower risk of mortality among HIV-infected adults initiating antiretroviral therapy in Guangxi, China. Sci Rep. 2019;9(1). [DOI] [PMC free article] [PubMed]
- 89.Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011;66(6):496–501. doi: 10.1136/thx.2010.156752. [DOI] [PubMed] [Google Scholar]
- 90.Ebissa G, Deyessa N, Biadgilign S. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia. AIDS Care. 2015;27(6):723–730. doi: 10.1080/09540121.2014.997180. [DOI] [PubMed] [Google Scholar]
- 91.Liotta G, Mancinelli S, Nielsen-Saines K, Gennaro E, Gennaro E, Scarcella P, Magid NA, Germano P, Jere H, Guidotti G, et al. Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique. PLoS One. 2013;8(8):e71653. doi: 10.1371/journal.pone.0071653. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Li N, Matchi E, Spiegelman D, Chalamilla G, Hertzmank E, Sando D, Sando MM, Liu E, Muya A, Fawzi W. Maternal mortality among HIV-infected pregnant women in Tanzania. Acta Obstet Gynecol Scand. 2014;93(5):463–468. doi: 10.1111/aogs.12374. [DOI] [PubMed] [Google Scholar]
- 93.Woodd SL, Kelly P, Koethe JR, Praygod G, Rehman AM, Chisenga M, Siame J, Heimburger DC, Friis H, Filteau S. Risk factors for mortality among malnourished HIV-infected adults eligible for antiretroviral therapy. BMC Infect Dis. 2016;16(1). [DOI] [PMC free article] [PubMed]
- 94.Chandrasekhar A, Gupta A. Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? Am J Clin Nutr. 2011;94(6):1703S–1715S. doi: 10.3945/ajcn.111.019018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Kendi C, Penner J, Koech J, Nyonda M, Cohen CR, Bukusi EA, Ngugi E, Meyer ACL. Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgrad Med J. 2013;89(1048):73–77. doi: 10.1136/postgradmedj-2012-130823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande MJ. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. BMC Infect Dis. 2019;19(1). [DOI] [PMC free article] [PubMed]
- 97.Kyeyune R, Saathoff E, Ezeamama AE, Löscher T, Fawzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014;14(1). [DOI] [PMC free article] [PubMed]
- 98.Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, Doro Altan A, Zimba Ida V, San Lio MM, De Luca A. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48(1):115–122. doi: 10.1086/593312. [DOI] [PubMed] [Google Scholar]
- 99.Jerene D, Endale A, Hailu Y, Lindtjøorn B. Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis. 2006;6. [DOI] [PMC free article] [PubMed]
- 100.Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52. doi: 10.1186/1471-2334-8-52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Dao CN, Peters PJ, Kiarie JN, Zulu I, Muiruri P, Ong'Ech J, Mutsotso W, Potter D, Njobvu L, Stringer JSA, et al. Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan women. AIDS Res Hum Retrovir. 2011;27(11):1149–1155. doi: 10.1089/aid.2010.0345. [DOI] [PubMed] [Google Scholar]
- 102.Masiira B, Baisley K, Mayanja BN, Kazooba P, Maher D, Kaleebu P. Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda. Glob Health Action. 2014;7:21843. doi: 10.3402/gha.v7.21843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, King CC, Wang JD. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13(4):513–519. doi: 10.1111/j.1365-3156.2008.02029.x. [DOI] [PubMed] [Google Scholar]
- 104.Sieleunou I, Souleymanou M, Schönenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural Centre in the far-North Province, Cameroon. Trop Med Int. 2009;14(1):36–43. doi: 10.1111/j.1365-3156.2008.02183.x. [DOI] [PubMed] [Google Scholar]
- 105.Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, Bernheimer I, Musinguzi N, Yiannoutsos CT, Martin JN. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr. 2013;63(2):e64–e71. doi: 10.1097/QAI.0b013e31828af5a6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, Chaisson RE, Grant AD, Churchyard GJ. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr. 2011;58(3):269–273. doi: 10.1097/QAI.0b013e31823219d1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Maman D, Pujades-Rodriguez M, Nicholas S, McGuire M, Szumilin E, Ecochard R, Etard JF. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. AIDS. 2012;26(11):1393–1398. doi: 10.1097/QAD.0b013e328352d054. [DOI] [PubMed] [Google Scholar]
- 108.Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782–793. doi: 10.1001/jama.296.7.782. [DOI] [PubMed] [Google Scholar]
- 109.Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, Schwarz M, Bbosa R, Muruta A, Meya DB, et al. Implementation and operational research: integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr. 2015;68(5):e69–e76. doi: 10.1097/QAI.0000000000000527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Tchounga BK, Hønge BL, Eholie SP, Coffie PA, Jespersen S, Wejse C, Dabis F, Geoffrey GS, Ekouevi DK. Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa. AIDS. 2016;30(17):2707–2714. doi: 10.1097/QAD.0000000000001232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Otwombe KN, Petzold M, Modisenyane T, Martinson NA, Chirwa T. Factors associated with mortality in HIV-infected people in rural and urban South Africa. Glob Health Action. 2014;7(1). [DOI] [PMC free article] [PubMed]
- 112.Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20(18):2355–2360. doi: 10.1097/QAD.0b013e32801086b0. [DOI] [PubMed] [Google Scholar]
- 113.Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, Kambugu A, Manabe YC, Kestens L, Colebunders R. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol. 2011;2011:758350. doi: 10.1155/2011/758350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodríguez M. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr. 2011;57(4):311–318. doi: 10.1097/QAI.0b013e318218a713. [DOI] [PubMed] [Google Scholar]
- 115.Liu E, Makubi A, Drain P, Spiegelman D, Sando D, Li N, Chalamilla G, Sudfeld CR, Hertzmark E, Fawzi WW. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS. 2015;29(11):1391–1399. doi: 10.1097/QAD.0000000000000705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Chang CA, Meloni ST, Eisen G, Chaplin B, Akande P, Okonkwo P, Rawizza HE, Tchetgen ET, Kanki PJ. Tuberculosis incidence and risk factors among human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy in a large HIV program in Nigeria. Open Forum Infect Dis. 2015;2(4):1–11. doi: 10.1093/ofid/ofv154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Bjerrum S, Oliver-Commey J, Kenu E, Lartey M, Newman MJ, Addo KK, Hilleman D, Andersen AB, Johansen IS. Tuberculosis and non-tuberculous mycobacteria among HIV-infected individuals in Ghana. Trop Med Int Health. 2016;21(9):1181–1190. doi: 10.1111/tmi.12749. [DOI] [PubMed] [Google Scholar]
- 118.Mupfumi L, Moyo S, Molebatsi K, Thami PK, Anderson M, Mogashoa T, Iketleng T, Makhema J, Marlink R, Kasvosve I, et al. Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS One. 2018;13(1). [DOI] [PMC free article] [PubMed]
- 119.Melkamu H, Seyoum B, Dessie Y. Determinants of tuberculosis infection among adult HIV-positives attending clinical care in Western Ethiopia: a case-control study. AIDS Res Treat. 2013;2013:279876. doi: 10.1155/2013/279876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Gedle D, Kumera G, Eshete T, Ketema K, Adugna H, Feyera F. Intestinal parasitic infections and its association with undernutrition and CD4 T cell levels among HIV/AIDS patients on HAART in Butajira, Ethiopia. J Health Popul Nutr. 2017;36(1):15. doi: 10.1186/s41043-017-0092-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Ageru TA, Koyra MM, Gidebo KD, Abiso TL. Anemia and its associated factors among adult people living with human immunodeficiency virus at Wolaita Sodo University teaching referral hospital. PLoS One. 2019;14(10):e0221853. doi: 10.1371/journal.pone.0221853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Chen YN, Wall KM, Fofana K, Navarro-Colorado C. Nutrition indicators as potential predictors of AIDS-defining illnesses among ARV-naïve HIVpositive adults in Kapiri Mposhi, Zambia 2008-2009. PLoS One. 2019;14(7). [DOI] [PMC free article] [PubMed]
- 123.Hussen S, Belachew T, Hussein N. Nutritional status of HIV clients receiving HAART: Its omplication on occurrence of opportunistic infection. The Open Public Health J. 2017;10(1).
- 124.Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe tropical disease hospital Johannesburg, South Africa. BMC Infect Dis. 2015;15:478. doi: 10.1186/s12879-015-1214-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Hughes S, Kelly P. Interactions of malnutrition and immune impairment, with specific reference to immunity against parasites. Parasite Immunol. 2006;28(11):577–588. doi: 10.1111/j.1365-3024.2006.00897.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Candiani TM, Pinto J, Cardoso CA, Carvalho IR, Dias AC, Carneiro M, Goulart EA. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais state, Brazil. Cad Saude Publica. 2007;23(Suppl 3):S414–S423. doi: 10.1590/S0102-311X2007001500009. [DOI] [PubMed] [Google Scholar]
- 127.Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, Lule JR, Coutinho A, Tappero J, Bunnell R. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371(9614):752–759. doi: 10.1016/S0140-6736(08)60345-1. [DOI] [PubMed] [Google Scholar]
- 128.Berhe N, Tegabu D, Alemayehu M. Effect of nutritional factors on adherence to antiretroviral therapy among HIV-infected adults: a case control study in northern Ethiopia. BMC Infect Dis. 2013;13:233. doi: 10.1186/1471-2334-13-233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Young S, Wheeler AC, McCoy SI, Weiser SD. A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. AIDS Behav. 2014;18(Suppl 5):S505–S515. doi: 10.1007/s10461-013-0547-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful hiv treatment—clinical points of view and practical considerations. Front Pharmacol. 2017;8:831. doi: 10.3389/fphar.2017.00831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, Shaukat M, Rewari BB. Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India. PLoS One. 2013;8(6):e66860. doi: 10.1371/journal.pone.0066860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Biset Ayalew M. Mortality and its predictors among HIV infected patients taking antiretroviral treatment in Ethiopia: a systematic review. AIDS Res Treat. 2017;2017. [DOI] [PMC free article] [PubMed]
- 133.Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study. BMC Infect Dis. 2019;19(1):305. doi: 10.1186/s12879-019-3924-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. J Am Med Assoc. 2010;304(3):303–312. doi: 10.1001/jama.2010.980. [DOI] [PubMed] [Google Scholar]
- 135.Pettersen PS, Brox IK, Naman E, Bruun JN, Dyrhol-Riise AM, Troseid M, Johannessen A. Antiretroviral treatment failure predicts mortality in rural Tanzania. Int J STDs AIDS. 2015;26(9):633–639. doi: 10.1177/0956462414548460. [DOI] [PubMed] [Google Scholar]
- 136.Scrimshaw NS. Historical concepts of interactions, synergism and antagonism between nutrition and infection. J Nutr. 2003;133(1):316S–321S. doi: 10.1093/jn/133.1.316S. [DOI] [PubMed] [Google Scholar]
- 137.Walson JL, Berkley JA. The impact of malnutrition on childhood infections. Curr Opin Infect Dis. 2018;31(3):231. doi: 10.1097/QCO.0000000000000448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Lonnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39(1):149–155. doi: 10.1093/ije/dyp308. [DOI] [PubMed] [Google Scholar]
- 139.Bourke CD, Berkley JA, Prendergast AJ. Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol. 2016;37(6):386–398. doi: 10.1016/j.it.2016.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Padmapriyadarsini C, Shobana M, Lakshmi M, Beena T, Swaminathan S. Undernutrition & tuberculosis in India: situation analysis & the way forward. Indian J Med Res. 2016;144(1):11–20. doi: 10.4103/0971-5916.193278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Chandrasekaran P, Saravanan N, Bethunaickan R, Tripathy S. Malnutrition: modulator of immune responses in tuberculosis. Front Immunol. 2017;8:1316. doi: 10.3389/fimmu.2017.01316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India Official Organ Indian Chest Soc. 2009;26(1):9. doi: 10.4103/0970-2113.45198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.FAO I, & WFP, : & WFP (world food Programme). In: Achieving Zero Hunger The critical role of investment in social protection and agriculture Rome, FAO. Edited by Nations FaAOotU; 2015.
- 144.World Health Organization. Guideline: nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013. [PubMed]
- 145.United Nations: World Bank list of economies (June 2019) available at https://hupo.org/resources/Documents/World%20Bank%20list%20of%20economies%20(June%202019).pdf. Accessed 18 Feb 2020. 2019.
- 146.Zanoni BC, Gandhi RT. Update on opportunistic infections in the era of effective antiretroviral therapy. Infect Dis Clinic North Am. 2014;28(3):501–518. doi: 10.1016/j.idc.2014.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.The Ethiopian Federal Ministry of Health: National Comprehensive HIV Prevention, Care and Treatment Training for Health care Providers. In.; 2017.
- 148.Filteau S, PrayGod G, Kasonka L, Woodd S, Rehman AM, Chisenga M, Siame J, Koethe JR, Changalucha J, Michael D, et al. Effects on mortality of a nutritional intervention for malnourished HIV-infected adults referred for antiretroviral therapy: a randomised controlled trial. BMC Med. 2015;13:17. doi: 10.1186/s12916-014-0253-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, et al. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Lancet HIV. 2018;5(5):e231–e240. doi: 10.1016/S2352-3018(18)30038-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150.PrayGod G, Friis H, Filteau S. Nutritional support to reduce mortality in patients with HIV? Lancet HIV. 2018;5(5):e202–e204. doi: 10.1016/S2352-3018(18)30047-X. [DOI] [PubMed] [Google Scholar]
- 151.World Health Organization: Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings available at https://apps.who.int/iris/bitstream/handle/10665/44033/9789241596701_eng.pdf. Accessed 19 Feb 2020; 2008.
- 152.Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–1908. doi: 10.1097/QAD.0b013e32830007cd. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data sets used and/or analyzed for this review are available from the corresponding author on reasonable request.